Lung Cancer

Experts from across oncology specialties highlight research being presented at the 2026 AACR Annual Meeting.

The FDA granted priority review to an I-DXd BLA for extensive-stage small cell lung cancer, a sBLA for zenocutuzumab in NRG1+ cholangiocarcinoma has been submitted to the FDA, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Christine M. Lovly, MD, PhD, FASCO, discuses acquired resistance in EGFR-mutated NSCLC, including detection and novel approaches to address it.

Susan Scott, MD, Julia Rotow, MD, and Enriqueta Felip, MD, PhD, debate the optimal choice of frontline regimen for EGFR-mutated NSCLC.

During a recent Peer Exchange, breast and lung cancer experts discussed comprehensive strategies for identifying and mitigating the AEs associated with ADCs.

The FDA has accepted and granted priority review to the BLA seeking the approval of I-DXd in ES-SCLC.

The FDA issued a CRL to RP1 plus nivolumab in advanced melanoma, accepted a NDA for the TLX101-Px imaging agent in glioma, and more.

Zosia Piotrowska, MD, MHS, discusses potential new TKIs, continued challenges, and ongoing frontline trials in EGFR exon 20 insertion–positive NSCLC

Wade Iams, MD, MSCI, discusses the management of LEMS in the context of SCLC.

Ticiana Leal, MD, discusses screening for LEMS in patients with SCLC.

An NDA for neladalkib in TKI-pretreated, advanced, ALK-positive NSCLC was submitted to the FDA.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in March 2026.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in March 2026 spanning tumor types.

A study shows that an AI pathology tool predicts whether a patient with extensive-stage small cell lung cancer will respond to platinum-based chemotherapy.

Dr Leal discusses variability in community practice and evolving treatment strategies for patients with small cell lung cancer.

Cemiplimab plus chemotherapy produced variable outcomes by genomic profile in patients with nonsquamous NSCLC.

Drs Rotow and Dietrich discuss the significance of the accelerated FDA approval of zongertinib (Hernexeos) for patients with HER2 TKD–mutated NSCLC.

Dr Shields discusses the realities of treating patients with SCLC in the community setting and how emerging therapies are shaping care delivery.

Lurbinectedin plus atezolizumab received CHMP recommendation as first-line maintenance for ES-SCLC that has not progressed following induction therapy.

The FDA cleared relacorilant plus nab-paclitaxel in ovarian cancer, the primary end point of the SENTRY trial in myelofibrosis was met, and more.

Gotistobart improved response rates and overall survival vs docetaxel in pretreated squamous NSCLC in stage 1 of the PRESERVE-003 trial.

The EMA's CHMP recommends marketing authorization for tarlatamab monotherapy for ES-SCLC following relapse during or after platinum-based chemotherapy.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Nicolas Girard, MD, PhD, discusses updated data from the phase 2 PALOMA-2 trial (NCT05498428) that were presented at the 2026 European Lung Cancer Congress.